CN113533584A - Simultaneous quantitative detection method and application of 2 blood-entering components in trichosanthes, allium macrostemon and pinellia ternate preparation - Google Patents
Simultaneous quantitative detection method and application of 2 blood-entering components in trichosanthes, allium macrostemon and pinellia ternate preparation Download PDFInfo
- Publication number
- CN113533584A CN113533584A CN202110976997.4A CN202110976997A CN113533584A CN 113533584 A CN113533584 A CN 113533584A CN 202110976997 A CN202110976997 A CN 202110976997A CN 113533584 A CN113533584 A CN 113533584A
- Authority
- CN
- China
- Prior art keywords
- blood
- mobile phase
- preparation
- allium macrostemon
- internal standard
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001522129 Pinellia Species 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 241000304531 Allium macrostemon Species 0.000 title claims abstract description 52
- 238000001514 detection method Methods 0.000 title claims abstract description 36
- 241000218989 Trichosanthes Species 0.000 title abstract description 29
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims abstract description 70
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 70
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 35
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims abstract description 35
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229960005305 adenosine Drugs 0.000 claims abstract description 35
- 229940029575 guanosine Drugs 0.000 claims abstract description 35
- 240000006023 Trichosanthes kirilowii Species 0.000 claims abstract description 17
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 claims abstract description 17
- 238000010811 Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Methods 0.000 claims abstract description 11
- 238000010828 elution Methods 0.000 claims abstract description 8
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 claims abstract description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims abstract description 4
- 239000000741 silica gel Substances 0.000 claims abstract description 4
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 4
- 238000012856 packing Methods 0.000 claims abstract description 3
- 210000002381 plasma Anatomy 0.000 claims description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 23
- 239000012086 standard solution Substances 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 13
- 239000007789 gas Substances 0.000 claims description 12
- 239000011550 stock solution Substances 0.000 claims description 11
- 238000003908 quality control method Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000004807 desolvation Methods 0.000 claims description 9
- 238000011160 research Methods 0.000 claims description 9
- UZKQTCBAMSWPJD-UQCOIBPSSA-N trans-Zeatin Natural products OCC(/C)=C\CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-UQCOIBPSSA-N 0.000 claims description 9
- UZKQTCBAMSWPJD-FARCUNLSSA-N trans-zeatin Chemical compound OCC(/C)=C/CNC1=NC=NC2=C1N=CN2 UZKQTCBAMSWPJD-FARCUNLSSA-N 0.000 claims description 9
- 238000005303 weighing Methods 0.000 claims description 9
- 229940023877 zeatin Drugs 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 238000001819 mass spectrum Methods 0.000 claims description 8
- 238000007865 diluting Methods 0.000 claims description 7
- 238000004445 quantitative analysis Methods 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims description 4
- 102100031497 Heparan sulfate N-sulfotransferase 1 Human genes 0.000 claims 1
- 101000588589 Homo sapiens Heparan sulfate N-sulfotransferase 1 Proteins 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 239000000306 component Substances 0.000 description 49
- 239000000523 sample Substances 0.000 description 44
- 241000700159 Rattus Species 0.000 description 39
- 239000003814 drug Substances 0.000 description 35
- 239000012071 phase Substances 0.000 description 32
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 24
- 235000013305 food Nutrition 0.000 description 20
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 15
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 10
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 10
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 10
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 10
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 10
- 244000078912 Trichosanthes cucumerina Species 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 10
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 10
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 10
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 6
- 235000019991 rice wine Nutrition 0.000 description 6
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 6
- 229940045145 uridine Drugs 0.000 description 6
- 238000003260 vortexing Methods 0.000 description 6
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 5
- MMDUKUSNQNWVET-WMRYYKKOSA-N 5,7-dihydroxy-2-(4-hydroxyphenyl)-6-[(2r,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]chromen-4-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1C1=C(O)C([C@H]2[C@@H]([C@@H](O)[C@@H](O)CO2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MMDUKUSNQNWVET-WMRYYKKOSA-N 0.000 description 5
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 5
- CVKKIVYBGGDJCR-SXDZHWHFSA-N Cucurbitacin B Natural products CC(=O)OC(C)(C)C=CC(=O)[C@@](C)(O)[C@@H]1[C@@H](O)C[C@]2(C)C3=CC[C@@H]4C(C)(C)C(=O)[C@H](O)C[C@@]4(C)[C@@H]3CC(=O)[C@@]12C CVKKIVYBGGDJCR-SXDZHWHFSA-N 0.000 description 5
- NDGBLTXHLFJWAK-UHFFFAOYSA-N N-p-coumaroyltyramine Natural products Oc1ccc(CCNC(=O)C2=CC(=O)Oc3ccccc23)cc1 NDGBLTXHLFJWAK-UHFFFAOYSA-N 0.000 description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- 229960000643 adenine Drugs 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 229940074360 caffeic acid Drugs 0.000 description 5
- 235000004883 caffeic acid Nutrition 0.000 description 5
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 5
- 229940114124 ferulic acid Drugs 0.000 description 5
- 235000001785 ferulic acid Nutrition 0.000 description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 5
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 5
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 5
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 5
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 5
- 235000009498 luteolin Nutrition 0.000 description 5
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 5
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 235000005493 rutin Nutrition 0.000 description 5
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 5
- 229960004555 rutoside Drugs 0.000 description 5
- NIABBGMPPWXWOJ-UHFFFAOYSA-N schaftoside Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C(OC2C(C(O)C(O)CO2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O NIABBGMPPWXWOJ-UHFFFAOYSA-N 0.000 description 5
- MMDUKUSNQNWVET-UHFFFAOYSA-N schaftozide Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C(C2C(C(O)C(O)CO2)O)=C(OC(=CC2=O)C=3C=CC(O)=CC=3)C2=C1O MMDUKUSNQNWVET-UHFFFAOYSA-N 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- RXGUTQNKCXHALN-BJMVGYQFSA-N trans-N-p-coumaroyl tyramine Chemical compound C1=CC(O)=CC=C1CCNC(=O)\C=C\C1=CC=C(O)C=C1 RXGUTQNKCXHALN-BJMVGYQFSA-N 0.000 description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 5
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 5
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229940075420 xanthine Drugs 0.000 description 5
- IXQKXEUSCPEQRD-NRNCYQGDSA-N (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)C=CC(C)(C)OC(=O)C)C=C2[C@H]1C[C@H](O)C(=O)C2(C)C IXQKXEUSCPEQRD-NRNCYQGDSA-N 0.000 description 4
- IHTCCHVMPGDDSL-ZJNDIJRCSA-N Cucurbitacin A Natural products O=C([C@@](O)(C)[C@H]1[C@@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(CO)[C@H]2CC=C2C(C)(C)C(=O)[C@H](O)C[C@@H]12)/C=C/C(OC(=O)C)(C)C IHTCCHVMPGDDSL-ZJNDIJRCSA-N 0.000 description 4
- QZJJDOYZVRUEDY-UHFFFAOYSA-N Dihydrocucurbitacin B Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(=O)C1(C)C QZJJDOYZVRUEDY-UHFFFAOYSA-N 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000013062 quality control Sample Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241001522232 Pinellia ternata Species 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LNSXRXFBSDRILE-UHFFFAOYSA-N Cucurbitacin Natural products CC(=O)OC(C)(C)C=CC(=O)C(C)(O)C1C(O)CC2(C)C3CC=C4C(C)(C)C(O)C(O)CC4(C)C3(C)C(=O)CC12C LNSXRXFBSDRILE-UHFFFAOYSA-N 0.000 description 1
- 206010049949 Intercostal neuralgia Diseases 0.000 description 1
- 206010035765 Pneumothorax traumatic Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 150000001904 cucurbitacins Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- PIGAXYFCLPQWOD-UHFFFAOYSA-N dihydrocucurbitacin I Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C PIGAXYFCLPQWOD-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- -1 nitrogenous compound Chemical class 0.000 description 1
- 238000012803 optimization experiment Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention provides a simultaneous quantitative detection method and application of 2 blood-entering components in a trichosanthes kirilowii and allium macrostemon pinellia preparation, wherein the detection method comprises the following steps: detecting the content of guanosine and adenosine in a plasma sample to be detected by using UPLC-MS/MS; chromatographic conditions are as follows: a reversed phase chromatographic column with silica gel particles as packing; mobile phase A: containing 0.1% formic acid water solution, and the mobile phase B is acetonitrile; gradient elution. The method can simultaneously determine the content of 2 blood-entering components of guanosine and adenosine in the trichosanthes and allium macrostemon pinellia preparation by limiting the parameters in the UPLC-MS/MS method and matching the parameters with each other, and is simple, rapid, accurate and reliable, high in sensitivity, good in specificity and good in stability.
Description
Technical Field
The invention relates to the technical field of in vivo metabolism of medicaments, in particular to a method for simultaneously and quantitatively detecting 2 blood-entering components in a trichosanthes kirilowii bulb, allium macrostemon and pinellia ternate preparation and application thereof.
Background
The classic famous formula trichosanthes kirilowii, allium macrostemon and pinellia ternate decoction is from the 'jin Kui Yao L ü e', is prepared by decocting trichosanthes kirilowii, allium macrostemon, pinellia ternate and rice wine, and is widely used for clinically treating angina pectoris coronary heart disease, rheumatic heart disease, ventricular tachycardia, intercostal neuralgia, mammary gland hyperplasia, chronic obstructive pulmonary disease, traumatic pneumothorax, senile cough and asthma, chronic bronchopneumonia, chronic cholecystitis and the like.
At present, researches on the snakegourd fruit, allium macrostemon and pinellia ternate decoction mainly focus on researches on chemical components, the pharmacodynamic substance basis of the snakegourd fruit, allium macrostemon and pinellia ternate decoction for playing the effects is not clear, and the detection means of effective components in blood is blank.
As is well known, the effective components of the traditional Chinese medicine can only exert curative effect after entering the blood of a human body, and how to quantitatively detect the trace effective components under the complex matrix condition becomes a difficult problem, so that in order to further deeply research the change situation of the trichosanthes and allium macrostemon pinellia preparation and the effective component change situation thereof in the blood and provide scientific basis for the effective substance basis of the efficacy in the trichosanthes and allium macrostemon pinellia preparation, the development of an accurate and reliable quantitative detection method for the blood-entering components of the trichosanthes and allium macrostemon pinellia preparation becomes a technical problem to be solved urgently at present.
Disclosure of Invention
Aiming at the defect that no quantitative detection method for blood-entering components of the trichosanthes and allium macrostemon pinellia preparation exists at present, the invention provides a simultaneous quantitative detection method for 2 blood-entering components in the trichosanthes and allium macrostemon pinellia preparation and application thereof, and the quantitative detection method can provide a basis for further screening quality markers and pharmacodynamic substance bases of the classical famous formula trichosanthes and allium macrostemon pinellia preparation.
In order to achieve the purpose of the invention, the embodiment of the invention adopts the following technical scheme:
a simultaneous quantitative detection method for 2 blood-entering components in a trichosanthes kirilowii maxim, allium macrostemon and pinellia ternate preparation comprises the following steps:
detecting the content of guanosine and adenosine in a plasma sample to be detected by using UPLC-MS/MS;
wherein, the chromatographic conditions are as follows: a reversed phase chromatographic column with silica gel particles as packing; mobile phase A: containing 0.1% formic acid water solution, and the mobile phase B is acetonitrile; the procedure for gradient elution was as follows:
0-1.5min, 95% mobile phase A, 5% mobile phase B;
1.5-2.0min, 95% → 80% mobile phase a, 5% -20% mobile phase B;
2.0-2.5min, 80% → 50% mobile phase a, 20% -50% mobile phase B;
2.5-3.5min, 50-95% of mobile phase A and 50-5% of mobile phase B;
3.5-5.0min, 95% mobile phase A, 5% mobile phase B;
the above percentages are volume percentages.
The method can simultaneously determine the content of 2 blood-entering components of guanosine and adenosine in the trichosanthes and allium macrostemon pinellia preparation by limiting the analysis parameters in the UPLC-MS/MS method and mutually matching the parameters, and the method for simultaneously and quantitatively detecting the 2 blood-entering components in the trichosanthes and allium macrostemon pinellia preparation is simple, rapid, reliable, high in sensitivity, good in specificity, good in accuracy, good in stability, lower in detection limit and quantitative limit.
The preparation comprises fructus Trichosanthis, Bulbus Allii Macrostemi and rhizoma Pinelliae decoction, fructus Trichosanthis, Bulbus Allii Macrostemi and rhizoma Pinelliae lyophilized powder, and fructus Trichosanthis, Bulbus Allii Macrostemi and rhizoma Pinelliae ointment.
Optionally, the preparation method of the trichosanthes and allium macrostemon pinellia ternate preparation comprises the following steps:
decocting fructus Trichosanthis, Bulbus Allii Macrostemi and rhizoma Pinelliae in rice wine, filtering, and making into decoction, unguent or lyophilized powder.
Preferably, the preparation method of the trichosanthes, allium macrostemon and pinellia ternate decoction comprises the following steps: weighing 10-15g of trichosanthes decoction pieces, 7-12g of allium macrostemon decoction pieces and 10-15g of pinellia ternate decoction pieces, adding 500mL of 300 rice wine, soaking for about 1.5-3.5h, decocting with strong fire until boiling, then decocting with slow fire for 15-25min, and filtering with 3-5 layers of gauze when the decoction pieces are hot.
More preferably, the preparation method of the trichosanthes, allium macrostemon and pinellia ternate decoction comprises the following steps: weighing 12.0g of trichosanthes decoction pieces, 9.0g of allium macrostemon decoction pieces and 12.0g of pinellia ternate decoction pieces, adding 400mL of rice wine, soaking for about 2 hours, decocting with strong fire until boiling, then decocting with slow fire for 20min, and filtering with 4 layers of gauze while hot to obtain the traditional Chinese medicine.
Optionally, the reverse phase chromatography column is an ACQUITY UPLC HSS T3 column.
Optionally, the chromatographic conditions further comprise: the column temperature is 30-40 ℃, the sample injection amount is 1.5-2.5 mu L, and the flow rate is 0.2-0.4 mL/min.
Preferably, the column temperature of the chromatographic conditions is 35 ℃, the sample injection amount is 2.0 μ L, and the flow rate is 0.3 mL/min.
Alternatively, the mass spectrometry conditions: the ion source is an ESI source, the capillary voltage is 3.2kv, and the desolvation gas is nitrogen; the temperature of the desolvation gas is 500 ℃, the flow rate of the desolvation gas is 600L/h, and the flow rate of the taper hole is 50L/h. The accuracy and stability of the quantitative detection method can be further improved by limiting mass spectrum conditions.
Optionally, the preparation method of the plasma sample to be tested comprises the following steps: and (3) placing the plasma sample into an EP tube, adding the internal standard solution, carrying out vortex mixing, adding acetonitrile, carrying out vortex mixing, centrifuging, and taking the supernatant, namely the plasma sample to be detected.
Optionally, the preparation method of the plasma sample to be detected further comprises the steps of taking blood, then placing the blood in a heparinized centrifugal tube, and centrifuging at 4000-.
Preferably, the preparation method of the blood plasma is as follows: blood is taken, and then the blood is placed in a heparinized centrifugal tube and centrifuged for 10min at 4500r/min to obtain plasma.
Optionally, the internal standard in the internal standard solution is zeatin.
Optionally, the concentration of zeatin in the internal standard solution is 3-8 μ g/mL.
Optionally, the internal standard solution is prepared by the following method:
weighing 5.00mg of zeatin in a 10mL volumetric flask, adding a methanol solution to fix the volume to a scale to obtain 0.5mg/mL internal standard stock solution, and diluting to obtain the internal standard solution.
The invention also provides application of the simultaneous quantitative detection method of 2 blood-entering components in the trichosanthes and allium macrostemon pinellia preparation in quality control research.
Such quality control studies include, but are not limited to, in vivo pharmacokinetic studies.
Compared with the prior art, the method has the advantages that the chromatographic conditions, the mass spectrum conditions, the internal standard substance selection and the sample pretreatment conditions are reasonably set, so that the detection sensitivity is improved, and the analysis time is shortened; the simultaneous quantitative analysis of two substances with similar polarities of guanosine and adenosine is realized; can be used for pharmacokinetic study of guanosine and adenosine after oral administration of the trichosanthes, allium macrostemon and pinellia ternate preparation; provides technical reference for simultaneous quantitative analysis of other components in the trichosanthes longstamen onion bulb pinellia preparation.
Drawings
FIG. 1 is a chromatogram of the proprietary experiment of example 2;
figure 2 is a plot of mean plasma adenosine and guanosine concentrations versus time for different modes of administration in the rat pharmacokinetic study of example 3.
Description of the drawings:
in the attached figure 1, A is a chromatogram of blank plasma of a rat, B is a chromatogram of the plasma of the rat containing a mixed reference solution and an internal standard substance, and C is a chromatogram of a plasma sample after gastric lavage administration of the rat;
in fig. 2, a is a blood concentration-time curve of adenosine in rats after three consecutive days of administration, B is a blood concentration-time curve of guanosine in rats after three consecutive days of administration, C is a blood concentration-time curve of adenosine in rats after a single administration, and D is a blood concentration-time curve of guanosine in rats after a single administration.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The traditional Chinese medicine is absorbed into blood after administration, chemical components with certain content in the body are possible to be potential bioactive components, although the content of some traditional Chinese medicine components in the compound is higher, the medicine can be restricted from playing the efficacy in the body due to limited absorption degree of a human body or faster component metabolism, and the factors of complex blood sample matrix and low sample content bring research and development difficulty to the detection of blood samples.
At present, researches on the snakegourd fruit, allium macrostemon and pinellia ternate decoction mainly focus on researches on chemical components, the basis of pharmacodynamic substances exerting efficacy in the snakegourd fruit, allium macrostemon and pinellia ternate decoction is not clear, the detection means of effective components in blood is blank, and the researches on multi-component pharmacokinetics of the snakegourd fruit, allium macrostemon and pinellia ternate decoction are not reported at home and abroad. On the basis of 84 prototype components in the currently identified trichosanthes, allium macrostemon and pinellia ternate decoction, 22 main representative components are selected, including trigonelline, uracil, thymidine, adenine, caffeic acid, uridine, guanine, guanosine, xanthine, adenosine, vanillic acid, 5-hydroxymethyl furfural, nicotinamide, rutin, quercetin, luteolin, protocatechuic acid, homoharringtonine, schaftoside, cucurbitacin B, N-p-coumaroyl tyramine and ferulic acid, so that the blood-entering prototype components of the trichosanthes, allium macrostemon and pinellia ternate decoction are determined, and the basis of drug effect substances of the trichosanthes, allium macrostemon and pinellia ternate decoction is discussed.
In order to establish a method for simultaneously and quantitatively detecting blood-entering components in a trichosanthes and allium macrostemon pinellia preparation, in the process of method development and method verification, in order to ensure multi-component synchronous detection, continuous exploration and optimization experiments are carried out on chromatographic conditions, mass spectrum conditions, a plasma sample processing mode and internal standard substance selection, an in vivo quantitative analysis method of the 22 components is researched, and the final result shows that only two components, namely adenosine and guanosine, have higher concentrations in vivo and can be accurately quantified. Specifically, the method for simultaneously and quantitatively detecting guanosine and adenosine in blood components in the trichosanthes kirilowii and allium macrostemon pinellia preparation researched and developed by the invention is as follows:
preparation of internal standard solution: weighing 5.00mg of zeatin in a 10mL volumetric flask, adding a methanol solution to fix the volume to a scale to obtain 0.5mg/mL internal standard stock solution, and diluting to obtain 4 mu g/mL internal standard solution for later use;
preparation of a plasma sample to be tested: precisely sucking 50 mu L of rat plasma sample, placing the rat plasma sample in 1.5mL of EP, precisely adding 10 mu L of the internal standard solution, uniformly mixing by swirling for 1min, then adding 140 mu L of acetonitrile solution, swirling for 5min, fully and uniformly mixing, centrifuging for 10min at 12000g, and obtaining supernatant as the plasma sample to be detected;
detecting the content of guanosine and adenosine in a plasma sample to be detected by using UPLC-MS/MS;
wherein, the mass spectrum condition is as follows: the ion source is an ESI source, the capillary voltage is 3.2kv, and the desolvation gas is nitrogen; the temperature of the desolvation gas is 500 ℃, the flow rate of the desolvation gas is 600L/h, and the flow rate of the taper hole is 50L/h; performing quantitative analysis by adopting an MRM mode;
chromatographic conditions are as follows: reversed phase chromatographic column with silica gel particles as filler, such as ACQUITY UPLC HSS T3 column; mobile phase A: formic acid water solution with the volume percentage of 0.1 percent, and the mobile phase B is acetonitrile; the elution mode is gradient elution; the column temperature is 30-40 ℃, the sample injection amount is 1.5-2.5 mu L, and the flow rate is 0.2-0.4 mL/min;
the procedure for gradient elution was as follows:
0-1.5min, 95% mobile phase A, 5% mobile phase B;
1.5-2.0min, 95% → 80% mobile phase a, 5% -20% mobile phase B;
2.0-2.5min, 80% → 50% mobile phase a, 20% -50% mobile phase B;
2.5-3.5min, 50-95% of mobile phase A and 50-5% of mobile phase B;
3.5-5.0min, 95% mobile phase A, 5% mobile phase B;
the above percentages are volume percentages.
Through a Multi-Reaction monitoring (MRM) positive ion scanning mode, combination of specific chromatographic detection conditions and selection of zeatin as an internal standard substance, the in vivo quantitative analysis method for the 22 components is researched, the blood concentrations of the 22 components in a rat body after administration are measured, pharmacokinetic parameters are calculated, the change rule of the traditional Chinese medicine in the body is known, and a basis is provided for further screening the quality markers and the pharmacodynamic substance basis of the classic famous formula trichosanthes kirilowii maxim and allium macrostemon pinellia ternate preparation.
The invention is further illustrated below in the following examples.
The experimental animals used in the following examples were provided by the laboratory animal center of Wenzhou university of medicine, SD male rats, weighing 200 + -20 g, 7-8 weeks old, and were acclimatized for one week in an environment of 22 + -2 deg.C, 55 + -10% relative humidity, and 12h light/dark cycle prior to the experiment.
The main experimental equipment and drugs used in the following examples are shown in tables 1-2 below.
TABLE 1 Main Experimental instruments and Equipment
Name of instrument | Manufacturer of the product | Model number |
Electronic balance | Beijing Sadolis Instrument systems, Inc | AB204N |
High-speed refrigerated centrifuge | eppendorf Co Ltd | 5920r |
UPLC-MS/MS | Waters corporation of America | |
Freeze dryer | NINGBO SCIENTZ BIOTECHNOLOGY Co.,Ltd. | SCIENTZ-10N |
Numerical control ultrasonic cleaner | KUNSHAN ULTRASONIC INSTRUMENTS Co.,Ltd. | HG64 |
Vortex mixer | Jiangsu Haiman Linbel Instrument manufacturing Co., Ltd | XW-80A |
TABLE 2 drugs and reagents
Reagent/medicinal material | Manufacturer/origin | Batch number |
Snakegourd fruit | Henan Anyang | GL20200501 |
Bulbus Allii Macrostemi | Shandong Xintai (a Chinese character of' Shandong | SDX20191001 |
Pinellia ternata (Thunb.) Breit | All the year round in Hubei province | BX201807091 |
Rice wine | Herb of Mipo | 20201202 |
Adenosine (I) | China Institute for food and drug control | 110879-201703 |
Guanosine | China Institute for food and drug control | 111977-201501 |
Uridine (uridine) | China Institute for food and drug control | 140660-202002 |
Adenine | China Institute for food and drug control | 110886-201102 |
Xanthine | China Institute for food and drug control | 140662-200802 |
Uracils | China Institute for food and drug control | 100469-201302 |
Vanillic acid | China Institute for food and drug control | 110776-201503 |
Trigonelline | China Institute for food and drug control | 110883-200502 |
5-hydroxymethylfurfural | Chengdu Desite Biotechnology Ltd | 111626-200906 |
Nicotinamide | China Institute for food and drug control | 100115-202005 |
N-P-Coumaroyl tyramine | Chengdu Desite Biotechnology Ltd | BP3309 |
Guanine and its preparing process | China Institute for food and drug control | 140718-202003 |
Thymidine | China Institute for food and drug control | 101215-201401 |
Caffeic acid | China Institute for food and drug control | 110885-201703 |
Rutin | China Institute for food and drug control | 100080-201811 |
Quercetin | China Institute for food and drug control | 100081-201610 |
Luteolin | China Institute for food and drug control | 111520-202006 |
Protocatechuic acid | China Institute for food and drug control | 110809-201906 |
Homoharringtonine | China Institute for food and drug control | 111533-201904 |
Schaftoside | China Institute for food and drug control | 111912-201703 |
Ferulic acid | China Institute for food and drug control | 110773-201915 |
Cucurbitacin B | China Institute for food and drug control | 111945-201301 |
Mass spectrum methanol | Merck Corp Ltd | |
Mass spectrum grade acetonitrile | Merck Corp Ltd | |
Chromatographic grade formic acid | ROE Scientific Inc | |
Deionized water | Hangzhou Wahaha Group Co.,Ltd. |
Example 1 study on method for measuring blood-entering component content of trichosanthes, allium macrostemon and pinellia ternate preparation
1. Preparation of the solution
1.1 preparation of Mixed control solutions
Precisely weighing control substances of trigonelline, uracil, thymidine, adenine, caffeic acid, uridine, guanine, guanosine, xanthine, adenosine, vanillic acid, 5-hydroxymethyl furfural, nicotinamide, rutin, quercetin, luteolin, protocatechuic acid, homoharringtonine, schaftoside, cucurbitacin B, N-p-coumaroyl tyramine and ferulic acid, respectively placing the control substances of 5.00mg in a 10mL volumetric flask, adding methanol to a constant volume to reach a scale, and obtaining each control substance stock solution with a final concentration of 0.5 mg/mL;
precisely measuring each reference substance stock solution respectively, mixing, and diluting with methanol to obtain mixed reference substance solution; the concentrations of each control in the mixed control solution were as follows: 250 mu g/mL of trigonelline; uracil 100. mu.g/mL; thymidine 50 μ g/mL; adenine 50. mu.g/mL; caffeic acid 250 mug/mL; uridine 50 μ g/mL; guanine 50 mug/mL; guanosine 50 mu g/mL; xanthine 10 μ g/mL; adenosine 50 μ g/mL; 500 mu g/mL of vanillic acid; 250 mu g/mL of 5-hydroxymethylfurfural; nicotinamide 50 μ g/mL; rutin is 100 mu g/mL; quercetin 100 μ g/mL luteolin 500 μ g/mL; protocatechuic acid 500. mu.g/mL; homoharringtonine 100 μ g/mL; schaftoside 250 mug/mL; cucurbitacin B100 mug/mL; 20 mu g/mL of N-p-coumaroyl tyramine; ferulic acid 250. mu.g/mL.
1.2 internal standard stock solution and preparation of internal standard solution
Precisely weighing 5.00mg of zeatin, adding a methanol solution into a 10mL volumetric flask, fixing the volume to a scale to obtain an internal standard stock solution with the final concentration of 0.5mg/mL, and then storing in a refrigerator at 4 ℃;
and precisely measuring the internal standard stock solution, and diluting the internal standard stock solution by methanol to prepare an internal standard solution of 4 mu g/mL.
1.3 preparation of lyophilized powder of Trichosanthes and Allium macrostemon pinellia Tuber for intragastric administration
Weighing 12.0g of trichosanthes decoction pieces, 9.0g of allium macrostemon decoction pieces and 12.0g of pinellia ternate decoction pieces, adding 400mL of rice wine to soak for about 2h, decocting with strong fire until boiling, then decocting with slow fire for 20min, filtering with 4 layers of gauze while hot, freeze-drying with a freeze dryer to obtain trichosanthes and allium macrostemon and pinellia ternate freeze-dried powder, and sealing and storing in a refrigerator at the temperature of-80 ℃.
When a rat is subjected to gastric lavage, the dosage of the snakegourd fruit, allium macrostemon and pinellia ternate freeze-dried powder is 1 time per day according to the dosage of 6g/kg each time, and the mass-volume ratio of the snakegourd fruit, allium macrostemon and pinellia ternate freeze-dried powder to pure water is 1.5g:1mL each time of gastric lavage.
1.4 preparation of the plasma sample to be tested
Precisely sucking 50 μ L rat plasma sample, placing in 1.5mL EP tube, precisely adding 10 μ L internal standard solution (obtained by diluting internal standard stock solution, with concentration of 4 μ g/mL), and vortexing for 1min to mix well. And then adding 140 mu L of acetonitrile solution, vortexing for 5min, fully mixing uniformly, centrifuging for 10min at 12000g, and taking supernatant, namely the plasma sample to be detected.
2. Detection of
Precisely absorbing a rat plasma sample, preparing the plasma sample to be detected according to the method under item 1.4, and injecting the plasma sample into UPLC-MS/MS for detection.
2.1 detection conditions
Conditions of Mass Spectrometry
Waters Quattro API triple quadrupole tandem mass spectrometer (Waters corporation, usa), electrospray ion source (ESI); the capillary voltage was 3.2 kv; the desolventizing gas is nitrogen; the temperature of the solvent gas is 500 ℃; the flow rate of the desolventizing gas is 600L/h; the cone orifice flow rate was 50L/h, the samples were quantitatively analyzed in MRM mode, and the experimental data were collected and processed using MassLynx software (version 4.1, Waters Corp.).
The quantitative ion, cone hole voltage and collision voltage of each control are shown in the following table.
TABLE 3
Chromatographic conditions
A chromatographic column: ACQUITY UPLC HSS T3 column (2.1X 100mm,1.8 μm)
Mobile phase: a: water (with 0.1% formic acid), B: acetonitrile
Column temperature: 35 deg.C
Sample introduction amount: 2 μ L
Gradient elution conditions are as follows:
TABLE 4 gradient elution conditions
Time (min) | A(%) | B(%) | Flow rate (mL/min) |
0.0 | 95 | 5 | 0.3 |
1.5 | 95 | 5 | 0.3 |
2.0 | 80 | 20 | 0.3 |
2.5 | 50 | 50 | 0.3 |
3.5 | 95 | 5 | 0.3 |
5 | 95 | 5 | 0.3 |
2.2 Final establishment of the detection conditions
The nitrogenous compound has response under the positive and negative ion detection mode of the electrospray ion source, the response under the positive ion mode is higher than that under the negative ion mode, and an obvious excimer ion peak can be detected under the positive ion mode.
The flow has great influence on the chromatographic behavior (peak symmetry and retention time) and the mass spectrum response of each object to be tested, methanol and acetonitrile are respectively used as mobile phases for investigation in the selection of the organic phase, and the result shows that acetonitrile as the organic phase has fast peak emergence, better peak shape, uniform distribution and high peak intensity, so that the acetonitrile is selected as the mobile phase. In the aspect of water phase additive selection, when no acid is added into the water phase, the tail of the chromatographic peak of the component to be detected is serious, the chromatographic behavior is obviously better after formic acid is added, the response of the object to be detected is also improved, and the result shows that the acetonitrile-0.1% formic acid water is used as the mobile phase and can obtain good ionic response.
The influence of 35 ℃ and 40 ℃ on chromatographic peaks is investigated, and the result shows that the influence of temperature on the separation of chromatographic peaks is small, and 35 ℃ is selected by combining the characteristics of the chromatographic column.
The finally determined method for measuring the content of the blood-entering components of the trichosanthes kirilowii, the allium macrostemon and the pinellia ternate preparation is the same as the detection condition under the item 2.1.
Example 2 methodological verification of blood-entering component content determination method of trichosanthes kirilowii, allium macrostemon and pinellia ternata freezing agent
Detection and quantification limits (determination of blood prototype components)
Calculating the required dilution times according to the signal-to-noise ratio of each control in the mixed control solution, properly diluting each control stock solution to obtain the concentration of each control in the mixed control solution, detecting according to the detection condition under 2.1, determining the limit of quantitation by the signal-to-noise ratio (S/N) being more than 10, determining the limit of detection by the signal-to-noise ratio (S/N) being more than 3, and expressing the limit of detection and the limit of quantitation of 22 components.
TABLE 522 limits of quantitation and detection of components in rat plasma
And (2) performing intragastric administration on 12 rats for 0, 10min, 20min, 30min, 1h, 2h, 4h, 8h, 12h, 24h, 36h and 48h according to the condition under the item 1.3, then drawing blood, placing the blood in a heparinized centrifuge tube, centrifuging at 4500r/min for 10min to obtain blood plasma, preparing blood plasma samples to be detected according to the condition under the item 1.4 respectively, and then performing content determination on the blood concentration of 22 components in the blood plasma samples to be detected according to the detection condition under the item 2.1.
According to detection, 13 components including trigonelline, thymidine, caffeic acid, vanillic acid, 5-hydroxymethyl furfural, rutin, quercetin, luteolin, protocatechuic acid, homoharringtonine, schaftoside, cucurbitacin B and ferulic acid are not detected in blood plasma. Although 7 components, that is, nicotinamide, N-p-coumaroyltyramine, uracil, adenine, guanine, xanthine, and uridine, were detected in plasma, the blood concentration was below the minimum quantitative limit of the apparatus, and accurate quantitative analysis could not be performed. Only two components, adenosine and guanosine, are present in high amounts in the plasma, allowing accurate quantification. Therefore, two components, adenosine and guanosine, were selected for subsequent pharmacokinetic studies.
The specificity is as follows: and comparing the blank rat plasma chromatogram, the plasma chromatogram of the added mixed reference solution and the internal standard solution, and the plasma sample chromatogram after the administration by intragastric administration of the rat, and inspecting the selectivity of the method.
The preparation method of the blank rat plasma sample comprises the following steps:
precisely sucking 50 mu L of rat plasma sample, placing the rat plasma sample in a 1.5mL EP tube, then adding 150 mu L of acetonitrile solution, vortexing for 5min, fully mixing uniformly, centrifuging at 12000g for 10min, and taking supernatant fluid, namely a blank rat plasma sample.
Rat plasma samples with the control and internal standard added were prepared as follows:
adding 1mL of the internal standard solution prepared under the item 1.2 into 14mL of acetonitrile to obtain an acetonitrile solution mixed with the internal standard for later use;
centrifuging rat plasma in a low-temperature centrifuge at 4 ℃ and 4500r/min for 15min, taking 50 mu L of supernatant, adding 10 mu L of mixed control solution prepared under item 1 and 140 mu L of acetonitrile solution mixed with internal standard, centrifuging at 12000r/min for 10min after vortex for 5min, and taking supernatant, namely the rat plasma sample added with the mixed control and the internal standard.
The preparation method of the plasma sample after the intragastric administration of the rat comprises the following steps:
adding 1mL of the internal standard solution prepared under the item 1.2 into 14mL of acetonitrile to obtain an acetonitrile solution mixed with the internal standard for later use;
after the rat is subjected to intragastric administration for 1h, blood is drawn, the rat is placed in a heparinized centrifuge tube and centrifuged at 4500r/min for 10min to obtain plasma, the plasma is centrifuged at 4500r/min for 15min at 4 ℃ in a low-temperature centrifuge, 50 mu L of supernatant is added into 150 mu L of acetonitrile solution mixed with the internal standard, the mixture is centrifuged at 12000r/min for 10min after 5min of vortex, and the supernatant is obtained.
Because adenosine and guanosine are endogenous substances and have certain background concentration in a rat body, a blank biological sample cannot be obtained, the method compares the chromatogram of the blank plasma sample, the plasma sample added with a mixed reference substance and the chromatogram of the plasma sample 1h after administration when carrying out specificity research, and determines specificity by taking whether the retention time of compounds in each ion monitoring channel is interfered or not as a basis.
As shown in fig. 1: a is the chromatogram of the blank plasma of the rat, B is the chromatogram of the plasma of the rat added with the mixed reference substance and the internal standard, and C is the chromatogram of the plasma sample after the administration of the intragastric administration of the rat. As can be seen from FIG. 1, under the above chromatographic conditions, other endogenous substances and metabolites do not interfere with the measurement of the analyte in the sample.
Linearity (drawing of standard curve of plasma sample)
Precisely sucking 10 mu L of mixed reference substance solution prepared under 1.1 and 50 mu L of blank plasma, carrying out vortex mixing for 1min, then processing according to the method under 1.4 to prepare a series of standard drug-containing plasma samples with different concentrations, carrying out sample injection test analysis according to the detection conditions under 2.1, carrying out regression operation by using a weighted (1/C2) least square method and carrying out linear regression by using the concentration (C) as a horizontal coordinate and the ratio of the peak area of the substance to be detected to the peak area of the internal standard substance as a vertical coordinate. The standard curves and lower limit of quantitation (LLOQ) for guanosine and adenosine are shown in the following table,
TABLE 6 Standard Curve and lower quantitation Limit for adenosine and guanosine in plasma samples
Name (R) | Linear equation of equations | R2 | Linear model (ng/mL) |
Adenosine (I) | Y=151.3x+3119.1 | 0.999 | 0.5-2500 |
Guanosine | Y=9.291x+1600.5 | 0.998 | 1-1500 |
As can be seen from the data in the table above, the correlation coefficient of the standard curve of each analyte is more than or equal to 0.99, which indicates that the UPLC-MS/MS analysis method has high sensitivity and good linear range.
Precision and accuracy
In the same day, the treatment method under item 1.4 is adopted to process and prepare the plasma samples containing the medicine with low, medium and high concentrations, 6 parts are respectively made for each concentration, and the accuracy and precision (RSD) in the day are calculated.
The plasma samples containing drug at three concentrations, low, medium and high, were processed and prepared according to the 1.4 treatment method, 3 portions for each concentration, and measured over 5 consecutive days. The mass concentration of the sample is calculated according to the standard curve of the day, the structure of the quality control sample is subjected to variance analysis, the accuracy and precision (RSD) of the day are calculated, and the detection results are shown in the table.
TABLE 7 precision and accuracy of adenosine and guanosine in plasma samples
As can be seen from the experimental data in the above table, the daily precision and the daytime precision of the 2 components are both less than 15%, and the accuracy is within 83.1% -94.4%, which indicates that the precision and the accuracy of the UPLC-MS/MS analysis method are good.
Matrix Effect and extraction recovery
Precisely sucking 10 mu L of mixed reference substance solution under the item 1.1 and 50 mu L of blank plasma, vortexing for 1min, uniformly mixing, processing plasma samples under the method of the item 1.4, preparing quality control samples (QC) containing high, medium and low 3 concentrations, wherein at least 6 samples under each concentration have a peak area marked as A;
precisely absorbing blank plasma 50 μ L and acetonitrile 150 μ L, vortexing for 8min, and mixing well. Centrifuge at 12000g for 10min, take 50. mu.L of supernatant, add to EP tube containing 10. mu.L of mixed control solution and 10. mu.L of internal standard solution (concentration 50ng/mL), and vortex for 1 min. Processing the plasma samples according to the method under item 1.4 to prepare quality control samples (QC) containing high, medium and low 3 concentrations, at least 6 samples at each concentration, and the peak area is marked as B;
precisely sucking 10 μ L of the mixed control solution and 50 μ L of ultrapure water, vortexing for 1min, mixing, and processing the sample under 1.4 to obtain quality control sample (QC) with high, medium, and low concentrations, wherein at least 6 samples with peak area of C are obtained at each concentration.
The extraction recovery rate is the ratio (A/B) of chromatographic peak area A of the extracted sample to chromatographic peak area B of the unextracted sample. The matrix effect was calculated from the peak area ratio (B/C) of the two treatments at the same concentration. The extraction recovery and matrix effect results are shown in the following table.
TABLE 8 matrix Effect and extraction recovery of adenosine and guanosine in plasma samples
As can be seen from the data in the table above, the matrix effects of adenosine and guanosine are 77.7% -90.4% and 81.9% -89.9%, respectively, which indicates that the matrix effects of the quality control samples of each concentration level of the 2 components all meet the detection requirements; the extraction recovery rate range of 2 components in rat plasma under the quality control level is 67.2% -78.6%, and the extraction recovery rate range is stable, and meets the measurement requirements of biological samples.
Stability of
Precisely sucking blank plasma of 50 μ L, preparing quality control sample (QC) containing high, medium and low 3 concentrations by referring to the method operation under item 1.4, and performing stability inspection on the components to be tested. Stability studies included short-term stability studies (quality control samples were stored at room temperature for 12h), long-term stability studies (quality control samples were stored in a-80 ℃ freezer for 15 days), and freeze-thaw stability studies (quality control samples were subjected to 3 freeze-thaw cycles), with the stability results shown in table 9.
TABLE 9 stability of adenosine and guanosine in plasma samples
As can be seen from the data in the table above, the short-term stability, the long-term stability and the freeze-thaw stability RSD of adenosine and guanosine are less than 15%, and all meet the detection requirements, which indicates that the stability of the UPLC-MS/MS analysis method is good.
Example 3 in vivo pharmacokinetic Studies in rats
12 healthy male SD rats are respectively subjected to intragastric administration of snakegourd fruit, allium macrostemon and pinellia ternate freeze-dried powder (operated according to item 1.3) according to the dose of 6g/kg, blood is taken immediately after 6 of the snakegourd fruit, allium macrostemon and pinellia ternate freeze-dried powder are subjected to intragastric administration for 3 days, the rats are subjected to blood taking after the intragastric administration for 3 days, the blood taking time points are 0min, 10min, 20min, 30min, 1h, 2h, 4h, 8h and 12h respectively, then the rats are placed in heparinized centrifuge tubes and centrifuged at 4500r/min for 10min, blood plasma is sucked and then processed according to the method under item 1.4, and the blood plasma sample to be detected obtained after processing is stored at the temperature of minus 20 ℃ for analysis. The plasma concentrations at different times were measured, and the DAS software analyzed pharmacokinetic parameters (version 3.0, shanghai, china), and the results of the major pharmacokinetic parameters of adenosine and guanosine after administration in different ways are shown in the table below, and the mean plasma concentration-time curves of adenosine and guanosine after administration in different ways are shown in fig. 2.
TABLE 10 pharmacokinetic parameters of adenosine and guanosine in rats after administration (n ═ 6)
As can be seen from the data in the above table in conjunction with FIG. 2, the C of adenosine and guanosine after a single administrationmaxValues of 875.46 + -439.12 ng/mL and 1137.51 + -407.19 ng/mL, respectively, and C of adenosine and guanosine after three consecutive days of administrationmaxThe values are 709.69 +/-343.75 ng/mL and 351.26 +/-85.94 ng/mL respectively, the blood concentration is relatively high, the medicine effect can be exerted only by chemical components with certain content in the body after the medicine is absorbed into the blood, and therefore adenosine and guanosine can be the main active components in the trichosanthes macrostemon pinellia preparation. In addition, the time to peak (T) of adenosine and guanosine following a single administrationmax) The values are 0.63 +/-0.77 h and 0.61 +/-0.70 h respectively, which shows that the trichosanthes and allium macrostemon pinellia preparation is absorbed quickly after entering a body and can quickly enter blood circulation to play a curative effect.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents or improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (9)
1. A simultaneous quantitative detection method for 2 blood-entering components in a trichosanthes kirilowii maxim, allium macrostemon and pinellia ternate preparation is characterized by comprising the following steps:
detecting the content of guanosine and adenosine in a plasma sample to be detected by using UPLC-MS/MS;
wherein, the chromatographic conditions are as follows: a reversed phase chromatographic column with silica gel particles as packing; mobile phase A: containing 0.1% formic acid water solution, and the mobile phase B is acetonitrile; the elution procedure was as follows:
0-1.5min, 95% mobile phase A, 5% mobile phase B;
1.5-2.0min, 95% → 80% mobile phase a, 5% -20% mobile phase B;
2.0-2.5min, 80% → 50% mobile phase a, 20% -50% mobile phase B;
2.5-3.5min, 50-95% of mobile phase A and 50-5% of mobile phase B;
3.5-5.0min, 95% mobile phase A, 5% mobile phase B;
the above percentages are volume percentages.
2. The method for simultaneously and quantitatively detecting 2 blood-entering components in the trichosanthes kirilowii bulb and pinellia ternate preparation according to claim 1, wherein the reversed phase chromatographic column is an ACQUITY UPLC HSST 3 column.
3. The method for simultaneously and quantitatively detecting 2 blood-entering components in the trichosanthes kirilowii maxim and allium macrostemon pinellia ternate preparation according to claim 1, wherein the chromatographic conditions further comprise: the column temperature is 30-40 ℃, the sample injection amount is 1.5-2.5 mu L, and the flow rate is 0.2-0.4 mL/min.
4. The method for simultaneously and quantitatively detecting 2 blood-entering components in the trichosanthes kirilowii maxim, allium macrostemon and pinellia ternate preparation according to any one of claims 1 to 3, is characterized in that the mass spectrum conditions are as follows: the ion source is an ESI source, the capillary voltage is 3.2kv, and the desolvation gas is nitrogen; the temperature of the desolvation gas is 500 ℃, the flow rate of the desolvation gas is 600L/h, and the flow rate of the taper hole is 50L/h.
5. The method for simultaneously and quantitatively detecting 2 blood-entering components in the trichosanthes kirilowii and allium macrostemon pinellia ternate preparation according to claim 1, wherein the preparation method of the blood plasma sample to be detected comprises the following steps: and (3) placing the plasma sample into an EP tube, adding the internal standard solution, carrying out vortex mixing, adding acetonitrile, carrying out vortex mixing, centrifuging, and taking the supernatant to obtain the plasma sample to be detected.
6. The method for simultaneously and quantitatively detecting 2 blood-entering components in the trichosanthes kirilowii bulb and allium macrostemon pinellia ternate preparation according to claim 5, wherein an internal standard substance in an internal standard solution is zeatin.
7. The method for simultaneously and quantitatively detecting 2 blood-entering components in the trichosanthes kirilowii bulb and pinellia ternate preparation according to claim 6, wherein the concentration of the zeatin in the internal standard solution is 3-8 μ g/mL.
8. The method for simultaneously and quantitatively detecting 2 blood-entering components in the trichosanthes kirilowii maxim, allium macrostemon and pinellia ternate preparation according to any one of claims 5 to 7, wherein the preparation method of the internal standard solution is as follows:
weighing 5.00mg of zeatin in a 10mL volumetric flask, adding a methanol solution to fix the volume to a scale to obtain 0.5mg/mL internal standard stock solution, and diluting to obtain the internal standard solution.
9. The use of the simultaneous quantitative determination method of 2 blood-entering components in the preparation of any one of claims 1-8 in the quality control research of the preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110976997.4A CN113533584A (en) | 2021-08-24 | 2021-08-24 | Simultaneous quantitative detection method and application of 2 blood-entering components in trichosanthes, allium macrostemon and pinellia ternate preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110976997.4A CN113533584A (en) | 2021-08-24 | 2021-08-24 | Simultaneous quantitative detection method and application of 2 blood-entering components in trichosanthes, allium macrostemon and pinellia ternate preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113533584A true CN113533584A (en) | 2021-10-22 |
Family
ID=78091998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110976997.4A Pending CN113533584A (en) | 2021-08-24 | 2021-08-24 | Simultaneous quantitative detection method and application of 2 blood-entering components in trichosanthes, allium macrostemon and pinellia ternate preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113533584A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115385901A (en) * | 2022-08-24 | 2022-11-25 | 乔穗桃 | Method for simultaneously separating schaftoside and trigonelline from pinellia ternata |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2385590A1 (en) * | 2010-03-12 | 2012-07-27 | Universidad De Murcia | Method of determination of nucleotides in foods by means of liquid chromatography of ionic pairs with detection by photodiodos coupled to spectrometry of masses. (Machine-translation by Google Translate, not legally binding) |
CN103926332A (en) * | 2013-01-15 | 2014-07-16 | 重庆医科大学 | Ultra performance liquid chromatography method for simultaneously determining contents of uridine, guanosine and adenosine in rhizoma pinelliae extract |
CN104777243A (en) * | 2015-01-29 | 2015-07-15 | 重庆医科大学 | HPLC method for simultaneously determining organic acids, nucleosides and ephedrine in pinellia tuber |
-
2021
- 2021-08-24 CN CN202110976997.4A patent/CN113533584A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2385590A1 (en) * | 2010-03-12 | 2012-07-27 | Universidad De Murcia | Method of determination of nucleotides in foods by means of liquid chromatography of ionic pairs with detection by photodiodos coupled to spectrometry of masses. (Machine-translation by Google Translate, not legally binding) |
CN103926332A (en) * | 2013-01-15 | 2014-07-16 | 重庆医科大学 | Ultra performance liquid chromatography method for simultaneously determining contents of uridine, guanosine and adenosine in rhizoma pinelliae extract |
CN104777243A (en) * | 2015-01-29 | 2015-07-15 | 重庆医科大学 | HPLC method for simultaneously determining organic acids, nucleosides and ephedrine in pinellia tuber |
Non-Patent Citations (4)
Title |
---|
JIN-JIN LU等: "Ultra-high performance liquid chromatography with ultraviolet andtandem mass spectrometry for simultaneous determination ofmetabolites in purine pathway of rat plasma", 《JOURNAL OF CHROMATOGRAPHY B》 * |
刘育强等: "HPLC法测定红花注射液中尿苷、鸟苷和腺苷含量", 《亚太传统医药》 * |
王朋展等: "HPLC法同时测定不同来源半夏及其伪品中9种核苷类成分的含量", 《药物分析杂志》 * |
隋利强等: "RP-HPLC法测定不同贮存年限半夏饮片中腺苷和鸟苷的含量", 《黔南民族医专学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115385901A (en) * | 2022-08-24 | 2022-11-25 | 乔穗桃 | Method for simultaneously separating schaftoside and trigonelline from pinellia ternata |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | LC–MS/MS determination and pharmacokinetic study of seven flavonoids in rat plasma after oral administration of Cirsium japonicum DC. extract | |
Chang et al. | Simultaneous determination and pharmacokinetic study of six flavonoids from Fructus Sophorae extract in rat plasma by LC–MS/MS | |
CN109239224B (en) | Method for simultaneously and quantitatively measuring 9 blood-entering components in spina date seed water extract | |
CN109324126B (en) | Method for simultaneously determining 9 chemical components in spina date seeds by using UPLC-MS/MS | |
Watterson et al. | Relative distribution of drugs in decomposed skeletal tissue | |
Ma et al. | Simultaneous determination of tetrahydropalmatine, protopine, and palmatine in rat plasma by LC-ESI-MS and its application to a pharmacokinetic study | |
Jung et al. | Simultaneous determination of puerarin and its active metabolite in human plasma by UPLC-MS/MS: Application to a pharmacokinetic study | |
Sheng et al. | Pharmacokinetic and excretion study of three secoiridoid glycosides and three flavonoid glycosides in rat by LC–MS/MS after oral administration of the Swertia pseudochinensis extract | |
Zhang et al. | Pharmacokinetics difference of multiple active constituents from decoction and maceration of Fuzi Xiexin Tang after oral administration in rat by UPLC–MS/MS | |
Jeong et al. | A sensitive UPLC–ESI–MS/MS method for the quantification of cinnamic acid in vivo and in vitro: Application to pharmacokinetic and protein binding study in human plasma | |
Men et al. | Study on pharmacokinetics of eight active compounds from Bufei-Huoxue Capsule based on UHPLC-MS/MS | |
Jeong et al. | Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study | |
CN113533584A (en) | Simultaneous quantitative detection method and application of 2 blood-entering components in trichosanthes, allium macrostemon and pinellia ternate preparation | |
CN112630339B (en) | Method for simultaneously and quantitatively measuring 4 blood-entering components in agilawood alcohol extract | |
CN103575830A (en) | Analysis method for four anthraquinones in blood plasma and application of four anthraquinones in pharmacokinetics | |
Fei-Yan et al. | Effect of diammonium glycyrrhizinate on entecavir pharmacokinetics in rats | |
CN113917031B (en) | Method for determining blood concentration of lung-tonifying and blood-activating capsule in vivo by UHPLC-MS/MS method | |
CN110687219B (en) | Detection method of suhuang cough-relieving capsule fingerprint and application thereof | |
Liu et al. | Effect of Carbonized Herba schizonepetae on the Bioavailability of Eight Active Components from Pulsatillae Decoction in its Particular Adsorption and Release Performance | |
Zhang | Dynamic Biodistribution of Icaritin and Its Phase-II Metabolite in Rat Tissues by Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry | |
CN113588855A (en) | Quality detection method of lindley eupatorium herb | |
He et al. | Effect of catnip charcoal on the in vivo pharmacokinetics of the main alkaloids of rhizoma Coptidis | |
CN112595787A (en) | Detection method and application of paeoniflorin, calycosin glycoside and amygdalin in plasma | |
CN103575820A (en) | Analysis method for five flavonoid glycosides in blood plasma and application of five flavonoid glycosides in pharmacokinetics | |
Xiao et al. | LC‐MS determination and pharmacokinetic studies of paeonol in rat plasma after administration of different compatibility of Su‐Xiao‐Xin‐Tong prescriptions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211022 |
|
RJ01 | Rejection of invention patent application after publication |